TEL-AVIV, Israel, May 4 (GLOBE NEWSWIRE) --
RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL)
(“RedHill” or the “Company”), a specialty biopharmaceutical company
primarily focused on the development and commercialization of late
clinical-stage, proprietary, orally-administered, small molecule drugs
for gastrointestinal and inflammatory diseases and cancer, today
reported its financial results for the quarter ended March 31, 2017.
The Company will host a conference call on Wednesday, May 3, 2017, at 9:00 am EDT to review the financial results and business highlights. Dial-in details are included below.
Financial highlights for the quarter ended March 31, 20174
Research and Development Expenses for
the first quarter of 2017 were $8.1 million, up 74% compared to the
first quarter of 2016 and up 9% compared to the fourth quarter of 2016.
The increase was mainly due to the ongoing Phase III and Phase II
studies with BEKINDA® (RHB-102)5 for
gastroenteritis and diarrhea-predominant irritable bowel syndrome
(IBS-D), respectively, the ongoing Phase III study with RHB-104 for
Crohn’s disease, ongoing studies with YELIVA® (ABC294640)6 for multiple indications and preparations for the upcoming confirmatory Phase III study with RHB-105 for H. pylori infection.
SOURCE : RedHill Biopharma Ltd.
No comments:
Post a Comment